Skip to NavigationSkip to content


Exscientia to collaborate with EQRx on drug development

Exscientia and EQRx have announced a strategic research and development collaboration agreement aiming to substantially accelerate the delivery of novel medicines.

The collaboration will leverage the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology, further expanding the breadth of EQRx’s pipeline of novel therapies.

Exscientia launch trial of third AI-designed molecule

Photo by Markus Spiske from Pexels

Exscientia has launched Phase I trials in the US of DSP-0038 for the treatment of Alzheimer’s disease psychosis, the third molecule created by the company’s artificial intelligence (AI) technology.

Joint research between Exscientia and Sumitomo Dainippon Pharma designed DSP-0038 to be a single small molecule that exhibits high potency as an antagonist for the 5-HT2A receptor and agonist for the 5-HT1A receptor, whilst selectively avoiding similar receptors and unwanted targets, such as the dopamine D2 receptor.

Exscientia enter first-ever AI cancer drug into Phase I trials

Cancer cell

Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first time ever.

Allergan R&D Chief named as Chairman of Exscientia's Board of Directors

Published on: 08/10/20

Artificial intelligence-driven drug discovery firm Exscientia has named industry veteran Dr David Nicholson, current Executive Vice President and Chief R&D Officer at Allergan, to take up the role of Chairman at the head of its Board of Directors, where he will guide the company’s business model strategy from discovery through to clinical use.

AI firm Exscientia appoints COO and Head of Drug Discovery

Published on: 31/01/20

AI drug discovery firm Exscientia has announced the appointment of Dr David Hallett as its Chief Operating Officer and Head of Drug Discovery.

Bringing 20 years of experience to the role, Dr Hallett’s primary remit will see him take responsibility for the company’s entire drug discovery portfolio, as well as managing pharma collaborations, joint ventures and pipeline projects. He will report to Exscientia Founder and CEO Professor Andrew Hopkins.

Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development, said: "The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures."

Celgene inks drug discovery deal worth at least £25m with AI firm Exscientia

Celgene has entered into a new three-year partnership with British artificial intelligence and drug discovery firm Exscientia to the value of at least $25 million, it has emerged, in a bid to galvanise small molecule drug discovery in oncology and autoimmunity.

Transactions stemming from the deal include this initial upfront payment in addition to “substantial” milestone payments subject to future regulatory and commercial successes.

The future is now: The transformative power of AI

Published on 05/02/18 at 02:26pm

With the technologies reaching exciting levels of maturity and adoption, Matt Fellows investigates how AI and machine learning can be transformative for some of pharma’s age-old problems.

Exscientia appoints Oxford Innovation Sciences founder and ex-Lansdowne CEO as Deputy Chairman

Published on: 11/12/17

Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its own proprietary AI-based drug discovery platform, has announced the appointment of Alex Snow to its Board of Directors as its Deputy Chairman.

Snow brings a rich background in investment, banking and entrepreneurship spanning 20 years to the role. He is the founder of Oxford Sciences Innovation (OSI) and is responsible for raising over £600 million commercialise science originating at the University of Oxford.

GSK signs $43 million AI-based drug discovery deal with Exscientia

With AI partnerships becoming increasingly common in the life sciences industry, it has emerged that GSK is to partner up with Scottish firm Exscientia in a $43 million deal in a bid to utilise the latter’s AI-driven platform to supercharge and streamline its drug discovery business.  

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches